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Abstract: The Cordyceps mushrooms have a long history as medicinal fungi. In Traditional Chinese Medicine,  
Cordyceps have been used to treat several conditions including cancers for thousand of years. Extracts from both mycelium 
and fruiting bodies of C. sinensis, C. militaris and other Cordyceps species showed significant anticancer activities by  
various mechanisms such as, modulating immune system and inducing cell apoptosis. Some polysaccharide components 
and cordycepin (3'-deoxyadenosine) have been isolated from C. sinensis and C. militaris, which acted as potent anticancer 
components. This review article aims to further elucidate the importance of Cordyceps mushrooms by summarizing the 
findings of some of the important research works concerning possible mechanism of anticancer activity of this mushroom.  
Keywords: C. sinensis, C. militaris, Cordycepin, Apoptosis, Immunomodulating, Anticancer activity. 
INTRODUCTION 
 There is a common saying, ‘Medicines and foods have a 
common origin’. Mushrooms are a manifestation of this idea 
in constituting both a nutritionally functional food and a 
source of physiologically beneficial medicine. Many centu-
ries ago, medicinal properties of mushrooms have been rec-
ognized in China, Korea and Japan. Although from ancient 
times, mushrooms have been treated as a special kind of nu-
traceutical, they have received a remarkable interest in recent 
decades. Major medicinal properties attributed to mush-
rooms include anticancer activity, antibiotic activity (di-
rected against bacteria, fungi and protozoa), antiviral activ-
ity, immune response-stimulating effects, anti-hypertensive 
and blood lipid lowering effects [1, 2]. Some mushrooms 
have gained special consideration due to their various me-
dicinal values in addition to nutritional importance. For ex-
ample, Lentinus edodes were reported to possess anti-tumor, 
antihypertensive, hypocholesterolemic and antibacterial 
activities [3-6]. Ganoderma lucidum has been proved to have 
anti microbial and anti-HIV effects [7, 8]. The hepatic and 
renal protective effects of G. lucidum in mice were also 
evaluated [9]. The beta-glucan polysaccharide of this mush-
room has potential application in immune surveillance and 
chemoprevention of cancer [2]. Mushrooms of Pleurotus 
species (P. ostreatus, P. sajor-caju, P. florida) were reported 
to have hypocholesterolemic activity in experimental rats 
[10, 11].  
 Cordyceps mushroom is a genus of ascomycete fungi that 
includes about 400 described species. All Cordyceps species 
are endoparasitoids, mainly on insects and other arthropods 
[12] These mushrooms have a long history as rare and exotic  
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medicinal fungi. They have been a highly regarded corner-
stone of traditional Chinese medicine for centuries; that ap-
parently have a number of far reaching medicinal effects [13, 
14]. Cordyceps mushrooms have been used to treat condi-
tions including respiration and pulmonary diseases; renal, 
liver, and cardiovascular diseases; hyposexuality and hyper-
lipidemia. It is also used in the treatment of immune disor-
ders and as an adjunct to modern cancer therapies (chemo-
therapy, radiation treatment and surgery) [12]. C. sinensis 
and C. militaris are the most common in use among the 
Cordyceps genus. 
ANTICANCER ACTIVITY OF CORDYCEPS 
SINENSIS  
 C. sinensis is a fungus that has been used for over 2000 
years in China as a treatment for a variety of conditions in-
cluding cancer. Many available evidences suggest that the 
efficacy of C. sinensis as an anti-neoplastic therapeutic agent 
is due to its role as an activator of immune responses. Ex-
tracts from both mycelium and fruiting bodies from C. sinen-
sis influence the immune system in various ways. In a study, 
water-extract from dried C. sinensis increased the median 
survival time of the allogeneic mice inoculated with Ehrlich 
ascites carcinoma cells (EAC) to 316% and syngeneic mice 
inoculated with Meth A fibrosarcoma (Meth A) to 312% of 
the control with no cytotoxic activity on either EAC or Meth 
A in vitro [15]. The water extract of this mushroom has been 
also proved beneficial in the prevention of tumor metastasis 
in mice as an adjuvant agent in cancer chemotherapy [16]. 
The natural killer cells (NK) activities of mouse were both in 
vivo and in vitro significantly augmented by intraperitoneal 
injection of the ethanol extract of C. sinensis [17]. The etha-
nol-extract also significantly decreased tumor weights and 
volumes in mice inoculated with Sarcoma-180 tumor cells. 
The extracts were demonstrated to exhibit phagocytosis  
enhancing activity as measured by carbon clearance in mice 
and caused a significant increase in an acid phosphatase  
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activity, representing lysosomal enzymes, suggesting that the 
anti-tumor activity of these fungi might be related to an im-
muno-stimulating function [18]. The ethyl acetate extract of 
C. sinensis mycelium was found to have strong anti-tumor 
activity on four cancer cell lines, MCF-7 breast cancer, B16 
mouse melanoma, HL-60 human premyelocytic leukemia 
and HepG2 human hepatocellular carcinoma [19]. Some 
specific fractions of extracts of C. sinensis, especially poly-
saccharides have been found to modify immune response 
more precisely. The conditioned medium from the polysac-
charide fraction of C. sinensis (PSCS)-stimulated blood 
mononuclear cells [PSCS-MNC-CM] had an activity that 
could significantly inhibit the proliferation of human leuke-
mic U937 cells resulting in a growth inhibition rate of 78-
83%. Furthermore, PSCS-MNC-CM treatment induced 
about 50% of the cells differentiating into mature mono-
cytes/macrophages expressing nonspecific esterase (NSE) 
and the surface antigens of CD11b, CD14 and CD 68. The 
levels of interferon (IFN)-gamma, tumor necrosis factor 
(TNF)-alpha and interleukin (IL)-1 were very low in normal 
MNC-CM but they were greatly increased in MNC-CM pre-
pared with PSCS stimulation. Antibody neutralization stud-
ies further revealed that the tumoricidal and differentiating 
effects of PSCS-MNC-CM were mainly derived from the 
elevated cytokines, especially IFN-gamma and TNF-alpha 
[20]. An exopolysaccharide fraction (EPSF), prepared from 
C. sinensis significantly enhanced the phagocytosis capacity 
of peritoneal macrophages and proliferation ability of spleen 
lymphocytes of H22 tumor (histocompatibility 22) and B16 
melanoma bearing mice, as well as inhibited the tumor 
growth in separate study. EPSF significantly promoted 
macrophages' TNF-alpha expression and spleen lympho-
cytes' cytotoxicity. EPSF also significantly elevated TNF-
alpha and IFN-gamma mRNA expression of splenic lym-
phocytes and thus elevated immunocytes' activity in H22 
tumor bearing mice [21, 22]. The EPSF from C. sinensis also 
has inhibitory effect on oncogene expression. The c-Myc, c-
Fos, and vascular endothelial growth factor (VEGF) levels in 
the lungs and livers of EPSF-treated mice were found to be 
significantly lower than those of untreated mice [23]. When 
lipopolysaccharide (LPS)-activated murine macrophage cell 
line R309 was exposed to the extracts C. sinensis, R309 in-
duced significant levels of IL-1. IL-2 induction was recog-
nized in T cell line LBRM-33 1A5 (1A5) cultures in the 
presence of IL-1 and phytohemagglutinin (PHA). However, 
no enhancement of IL-2 production by C. sinensis was dis-
cerned in 1A5 cultures with IL-1 and PHA, i.e., direct action 
of C. sinensis was not found on IL-2 production of 1A5. 
PHA-stimulated 1A5 exposed to C. sinensis induced IL-2 
without IL-1 when co-cultured with LPS-activated R309 as a 
source of IL-1 [24]. C. sinensis, either alone or with IFN-
gamma induction, increased the MHC class II antigen ex-
pression on hepatoma cell line HA22T/VGH, which makes 
the host immune surveillance more effective against tumor 
cells with down-regulated MHC class II antigen expression 
[25]. In leukemia patients, C. sinensis augmented the NK 
cell activity and also improved the CD16 marker expression 
on lymphocytes and the binding capacity to K562 cells [26]. 
In breast cancer, the oral C. sinensis did not reduce primary 
tumor growth but reduced lung metastasis occurrence in a 
surgical excision model of metastatic mammary carcinoma. 
The reduction in metastases growth is supposed to due to the 
effects of macrophage-derived factors on tumor cell cycle, 
NK cell activation and other immunostimulating activities 
[27, 28].  
 Although the immunomodulating activity of C. sinensis 
is mainly responsible for its anticancer activity, it is not so 
simply described and only exact mechanism. Directly or 
indirectly many other metabolic and genetic pathways are 
responsible. Extensive research works have been done to 
evaluate the mechanism of anticancer activity of C. sinensis 
and the most significant mechanism has been found to influ-
ence apoptosis. In a study, the ethyl acetate extract of myce-
lium of C. sinensis induced the characteristic apoptotic 
symptoms in human premyelocytic leukemia cells (HL-60), 
DNA fragmentation and chromatin condensation. The acti-
vation of caspase-3 and the specific proteolytic cleavage of 
poly ADP-ribose polymerase were detected during the 
course of apoptosis induction. These results suggest that this 
extract inhibited cancer cell proliferation by inducing cell 
apoptosis [29]. The involvement of caspase-8 with caspase-3 
was also found in C. sinensis induced apoptosis in MA-10 
mouse Leydig tumor cells [30]. Components from Cordy-
ceps induce tumor cell apoptosis through both extrinsic and 
intrinsic pathways. Two new epipolythiodioxopiperazines, 
named gliocladicillins A and B, from Cordyceps-colonizing 
fungi inhibited growth of HeLa, HepG2 and MCF-7 tumor 
cells by arresting the cell cycle at G(2)/M phase and induced 
apoptosis through up-regulation of expression of p53, p21, 
and cyclin B and activation of caspases-8, -9 and -3 [31]. 
Furthermore, EPSF of C. sinensis decreased the levels of 
Bcl-2 in the lungs and livers [22]. The antitumor activity of 
C. sinensis by inducing apoptosis was also found in human 
colorectal (HT-29 and HCT 116), hepatocellular (Hep 3B 
and Hep G2) carcinoma cells [32] and human oral squamous 
cancer cell line (OEC-M1) [33]. Interestingly, Tang et al. 
[34] reported that C. sinensis reduced Angiotensin II induced 
NRK-52E cell apoptosis, which may be part of its mecha-
nism of the protective effects on hypertensive renal damage. 
 The antioxidant activity of C. sinensis components is also 
responsible for its anticancer property. The ethanolic extract 
of C. sinensis was found to have inhibitory effect on lipid 
peroxidation and protective effect on 4-nitroquinoline oxide-
triggered DNA lesion in V79 hamster cells [35]. The poly-
saccharide component of C. sinensis has been found to in-
hibit the tumor growth of H22-bearing mice by modulating 
the antioxidant enzymes activity such as enhancing superox-
ide dismutase (SOD) activity of liver, brain and serum as 
well as glutathione peroxidase (GPx) activity of liver and 
brain in tumor-bearing mice [36]. Wang et al. [32] reported 
the free radical scavenging activity of C. sinensis. As free 
radicals are responsible for oxidative damage of apoptotic 
genes, by scavenging free radicals, C. sinensis protects apop-
totic genes and induces the apoptosis of cancer cells. 
ANTICANCER ACTIVITY OF CORDYCEPS 
MILITARIS 
 The mushroom C. militaris has been used for a long time 
in eastern Asia as a nutraceutical and in traditional Chinese 
medicine as a therapeutic agent for cancer patients. C. mili-
taris has been found good for inhibiting the growth of tumor, 
prolonging the survival period of mice implanted with S180 
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sarcoma cells and inhibiting the growth and metastasis of 
Lewis pneumonic cancer in the implanted mice [37]. Water 
extract of C. militaris inhibited growth of human umbilical 
vein endothelial cells (HUVEC) and human sarcoma cell line 
HT1080. This mushroom extract also reduced metalloprote-
inase 2 (mmp2) gene expression in HT1080 and basic fibro-
blast growth factor (bFGF) gene expression in HUVECs 
[38]. Recently, a cytotoxic protease was purified from  
the dried fruiting bodies of C. militaris, which exhibited  
cytotoxicity against human breast and bladder cancer cells 
[39].  
 Like C. sinensis, the most significant anticancer mecha-
nism of C. militaris was found by inducing cell apoptosis. In 
a study, Park et al. [40] observed that the aqueous extract of 
C. militaris (AECM) inhibited cell growth of human leuke-
mia U937 cells by morphological change and apoptotic cell 
death such as formation of apoptotic bodies and DNA frag-
mentation. They also observed the down-regulation of anti-
apoptotic gene bcl-2 expression and proteolytic activation of 
caspase-3 in AECM-treated U937 cells. But AECM did not 
affect the pro-apoptotic gene bax expression and activity of 
caspase-9. The hot water extract of C. militaris was also 
found to induce apoptosis in the human premyelocytic leu-
kemia HL-60 cells and the activation of caspase-3 and the 
specific proteolytic cleavage of Poly ADP-ribose polymerase 
(PARP) were detected during the course of apoptosis [41]. In 
addition to the activation of caspase-3, the AECM-induced 
apoptosis may relate to the inactivation of Akt (an oncogene) 
in human breast cancer MDA-MB-231 cells [42]. In another 
study, the growth inhibition and apoptosis induction by the 
water extract of C. militaris (WECM) treatment in human 
lung carcinoma A549 cells were found associated with the 
induction of Fas expression, catalytic activation of caspase-
8, and Bid cleavage. Activation of caspases, downregulation 
of anti-apoptotic gene bcl-2 expression, and upregulation of 
pro-apoptotic Bax protein were also observed in WECM-
treated cancer cells. In addition, WECM exerted a dose-
dependent inhibition of telomerase activity via down-regula- 
tion of human telomerase reverse transcriptase (hTERT),  
c-Myc and Sp1 expression. The data indicated that WECM 
induced the apoptosis of A549 cells through a signaling cas-
cade of death receptor-mediated extrinsic and mitochondria-
mediated intrinsic caspase pathways and diminishing the 
telomerase activity through the inhibition of hTERT tran-
scriptional activity [43].  
ANTICANCER ACTIVITY OF OTHER CORDYCEPS 
SPECIES 
 Three different polysaccharide-peptide complexes 
(PPCs) were produced by submerged mycelial culture of a 
rare entomopathogenic fungus Cordyceps sphecocephala 
and their anticancer activities were investigated in human 
hepatocarcinoma (HepG2) and neuroblastoma (SK-N-SH) 
cells. In this study, PPC-induced apoptosis of both cancer 
cells was found which was associated with intracellular 
events including DNA fragmentation, activation of caspase-
3, and modulation of Bcl-2 and Bax and no cytotoxicity 
against normal cells was reported [44].  
 A water-insoluble extracellular glucan (CO-1) was iso-
lated from the precipitate formed on incubation of the culture 
filtrate of Cordyceps ophioglossoides and this CO-1 strongly 
inhibited the growth of Sarcoma 180 solid-type tumor [45]. 
The effects of protein-bound polysaccharide (SN-C) ex-
tracted from C. ophioglossoides on the growth of trans-
planted allogeneic and syngeneic murine tumors were stud-
ied and it was found that SN-C given by intraperitoneal ad-
ministration suppressed the growth of sarcoma-180 trans-
planted subcutaneously in mice. SN-C also showed a signifi-
cant cytocidal effect on cultured tumor cells but did not af-
fect delayed-type hypersensitivity (DTH) in normal mice 
[46]. A protein-bound galactosaminoglycan (CO-N) was 
isolated from SN-C of C. ophioglossoides. When given in-
traperitoneally to mice, CO-N inhibited the proliferation of 
sarcoma 180 cells inoculated into the peritoneal cavity and 
exhibited a marked life-prolonging effect against ascitic tu-
mors such as Ehrlich carcinoma. CO-N also showed an in-
hibitory effect against solid Ehrlich carcinoma when given 
intratumorally and significantly inhibited the growth of a 
syngeneic solid tumor (MM46 mammary carcinoma) upon 
intravenous administration at a low dose [47]. 
CORDYCEPIN: AN ANTICANCER AGENT FROM 
CORDYCEPS SPECIES 
 Cordycepin, or 3'-deoxyadenosine, is a derivative of the 
nucleoside adenosine, differing from adenosine by the 
absence of oxygen in the 3' position of its ribose part. 
Cordycepin was isolated from the water extract of C. 
sinensis [33, 48]. Later the major component of the butanol 
fraction of C. militaris was also identified as cordycepin by 
high performance liquid chromatography [49]. Because 
cordycepin is similar to adenosine, RNA polymerase cannot 
discriminate between the two and when incorporated into a 
growing RNA molecule, cordycepin prevents further elonga-
tion, thus producing a prematurely terminated RNA mole-
cule [50]. 
 Orally administered cordycepin inhibited B16-BL6 
melanoma cell growth in mice with no adverse effects [48]. 
Further study demonstrated that cordycepin inhibited the 
proliferation of B16-BL6 cells by stimulating adenosine A3 
receptors followed by the Wnt signaling pathway, including 
GSK-3beta activation and cyclin D1 inhibition [51]. Cordy-
cepin markedly inhibited the phosphorylation of Akt and p38 
in dose-dependent manners in LPS-activated macrophage. 
Moreover, cordycepin suppressed TNF-alpha expression, 
Ikappa B alpha phosphorylation and translocation of nuclear 
factor-kappa B (NF-kappa B) [49]. Cordycepin-induced 
apoptosis is also reported. In MA-10 cells (a mouse Leydig 
tumor cell line), cordycepin induced DNA fragmentation, 
declined the percentage of G1 and G2/M phase cells, in-
creased the percentages of subG1 phase cells suggesting 
cordycepin induced MA-10 cell apoptosis. Moreover, west-
ern blotting analysis showed that cordycepin induced 
caspase-9, caspase--3 and caspase--7 protein expressions, but 
not caspase-8 [52]. In another study, cordycepin significantly 
induced cell apoptosis in OEC-M1 human oral squamous 
cancer cells [23]. It was also suggested that the effect of 
cordycepin on the growth of tumor cells was significantly 
related to the metabolism-associated protein expression in-
duced by cordycepin [53]. Platelet aggregation induced by 
cancer cells is an indispensable step for hematogenic metas-
tasis and it was showed that cordycepin had an inhibitory 
effect on hematogenic metastasis of B16-F1 melanoma cells 
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via blocking of ADP-induced platelet aggregation in vivo 
[54]. A novel molecular mechanism for the anti-tumor ef-
fects of cordycepin in two different bladder cancer cell lines, 
5637 and T-24 cells has been revealed by Lee et al. [55]. 
They reported that cordycepin treatment during cell-cycle 
progression resulted in significant growth inhibition, which 
was largely due to G2/M-phase arrest and resulted in an up-
regulation of p21WAF1 expression, independent of the p53 
signaling pathway. Moreover, treatment with cordycepin 
induced phosphorylation of JNK (c-Jun N-terminal kinases). 
Blockade of JNK function using SP6001259 (JNK-specific 
inhibitor) and small interfering RNA (si-JNK1) rescued 
cordycepin-dependent p21WAF1 expression, inhibited cell 
growth and decreased cell cycling proteins.  
 Derivatives of cordycepin have also showed anticancer 
activity. In an experiment, 1-O-Acetyl-2,5-di-O-p-chloro- 
benzoyl-3-deoxy-D-ribofuranose, derived from cordycepin 
was coupled with trimethylsilylated derivatives of N4-
propionylcytosine, N4-p-toluoyl-5-fluorocytosine and 5-
fluorouracil in the presence of trimethylsilyl trifluoro-
methanesulfonate (TMS-triflate) to give fully acylated  
nucleosides. Selective removal of the N4-propionyl group  
of these nucleosides by treatment with hydrazine hydrate 
gave 2',5'-di-O-p-chlorobenzoyl-3'-deoxycytidine, deamina-
tion of which with sodium nitrite in trifluoroacetic acid af-
forded 2',5'-di-O-p-chlorobenzoyluridine in good yield. The 
acylated nucleosides and 2',5'-di-O-p-chlorobenzoyluridine 
were saponified to give free 3'-deoxycytidine, 5-fluoro-3'-de- 
oxycytidine, 3'-deoxyuridine, and 5-fluoro-3'-deoxyuridine, 
respectively. These 3'-deoxyribonucleosides were then ex-
amined for growth-inhibitory effects on mouse leukemic 
L5178Y cells, and their IC50 (inhibitory concentration 50) 
values were found 1.8, 33, 6.5, and 18 (microgram/ml) re-
spectively [56]. Other nucleotide derivatives also exist which 
showed anticancer activities, such as, forodesine (also 
known as Immucillin H; IUPAC name: 7-[(2S,3S,4R,5R)-
3,4-dihydroxy-5-(hydroxymethyl)-2-pyrrolidinyl]-1,5-dihydro- 
pyrrolo[2,3-e]pyrimidin-4-one) is a inhibitor of purine nu-
cleoside phosphorylase, which is recognized as a potential 
target for the treatment of patients with T-cell malignancies 
and also B-cell chronic lymphocytic leukemia [57, 58]. 
CONCLUSIONS 
 Currently, in some parts of the world, there is a renais-
sance of interest in traditional remedies. Most of the investi-
gators believe that traditional medicine is a promising source 
of new therapeutics. Mushrooms have a notable place in 
folklore or traditional medicine throughout the world. Me-
dicinal mushrooms are now the subject of study for many 
ethnobotanists and medical researchers. The ability of some 
mushrooms, especially Cordyceps to inhibit tumor growth 
and enhance aspects of the immune system has been a sub-
ject of research for approximately 50 years. As cancer is one 
of the most complicated diseases and its pathogenic mecha-
nism is diverse, therapeutic attempts are being taken against 
cancer from different angles. The cancer protecting activities 
of Cordyceps are widely reported and established and now it 
is the time to look for the cancer preventing activity of this 
mushroom more precisely. Extensive research with Cordy-
ceps mushrooms may contribute to the discovery of new 
anticancer strategies. 
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